BRUPHARMA
ActiveSummary
The computed 12-month bankruptcy probability of BRUPHARMA is 3.1% (moderate). The 2024 annual accounts show negative equity (-€46,276) and a net result of €23,906. Equity is growing by about 20% per year across the filed financial years. Its solvency ranks better than 9% of 9,537 sector peers (NACE 47, financial year 2024). The company has been active since 1997 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Board 1
Permanent representatives 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| TWEE-DE |
|
Owners and capital
Owners
1 ownerChain of control
- TWEE-DE
- BRUPHARMA
Highest known parent: TWEE-DE. The sources do not say who stands above it.
Owners 1
- TWEE-DEparent99%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- 11-01-2024 Capital stated in the deed · €61,973.38 · 2,500 shares